2[2]Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998; 25(5): 2
3[3]Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol,1997;24 : 6
4[4]Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol, 2001 ; 96(4) : 1019
5[5]Silverstein FE, Faich G, Goldstein JL, et al.Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000 ; 284(10): 1247
6[6]Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.J Rheumatol,2000;27(8) : 1876
